Infectious complications associated with tocilizumab following chimeric antigen receptor T-cell therapy
{{output}}
PurposeChimeric antigen receptor (CAR) T-cell therapy has reshaped the outlook for patients with relapsed or refractory hematologic malignancies. In pivotal trials, infections occurred in 19-56% and 42-69% of patients receiving CD19- and B-cell maturation anti... ...
